Dynavax (DVAX) Price Target Adjusted to $60 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Dynavax (DVAX) Bullish Stance Reiterated at Jefferies Following R&D Day
December 12, 2014 9:14 AM ESTJefferies analyst Thomas Wei reiterated a Buy rating and $30 price target on Dynavax Technologies (NASDAQ: DVAX) following the company's R&D day where they reiterated the Heplisav timeline (data by YE15) and provided an overview of new development plans for SD-101 for... More
